Concentrix (CNXC) Reports 12.1% Revenue Growth

By Tamara Parker • Saturday, March 23 10:16 • Permanent Link

Marnix Lux SA has released its unaudited interim condensed consolidated financial statements for the period ended June 30, 2023, and for the three and six months ended June 30, 2022. The financial statements provide a detailed breakdown of the company's performance and key metrics, offering valuable insights into its financial health and operational activities.

Revenue for the three-month period ended June 30, 2023, amounted to €642.1 million, reflecting a notable increase of 9.1% compared to the same period in 2022, where revenue was €588.4 million. Similarly, for the six-month period ended June 30, 2023, revenue stood at €1,320.4 million, marking a significant 12.1% increase from the €1,177.9 million reported for the six months ended June 30, 2022.

Purchases consumed and other external expenses totaled €83.9 million and €173.0 million, respectively, for the three-month period ended June 30, 2023, compared to €80.1 million and €166.9 million for the same period in 2022.

Personnel expenses in the income statement were detailed, providing insight into the company's allocation of resources. Additionally, net charges to amortization, depreciation, impairment, and provision were outlined, showing amounts of €40.0 million and €80.7 million for the three and six months ended June 30, 2023, compared to €42.7 million and €79.1 million for the same periods in 2022.

The financial statements also disclosed 'other operating income and expenses,' which encompassed various components such as amortization of customer relationships and technologies, costs related to M&A projects, acquisition of business, and transformation project costs.

Furthermore, net financial income or expenses were detailed, providing insights into the company's interest expense, loan issuance costs, and financial costs on undrawn credit facilities. The increase in net financial income or expenses during the six-month period ended June 30, 2023, compared to the same period in 2022, was also highlighted.

For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.